Jack Anders

CFO Jack Anders sells 20,000 shares ($3.4M) via pre-arranged 10b5-1 plan; retains 123.3K shares plus 20,600 stock options at unprofitable biotech.

Jack Anders, CFO of Revolution Medicines, executed 4 separate sales totaling 20,000 shares for $3,366,604.47 on 2026-06-24, reducing his direct holdings by 14.0% while retaining 123.3K non-derivative shares and 20,600 stock options. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-03-24, meaning the sales were scheduled rather than discretionary. The stock has appreciated 19.0% over the prior 30 days and 96.8% over 90 days, currently trading at $182.08, yet the company remains unprofitable with a net loss of $453.8M in the most recent fiscal year and $0.00 revenue in the latest quarter. Anders' prior sales at this ticker show mixed timing outcomes: his January 2026 sale preceded a 0.5% 30-day decline, while his November 2025 sale coincided with subsequent 22.7% 30-day gains, suggesting no consistent pattern of foresight at this company. The scheduled nature of this divestiture and substantial retained position (both common and derivative) constrains inference about conviction, but the transaction occurs amid significant recent stock appreciation in a company with no established profitability path.

CFO Anders Jack sold 10,000 shares of RVMD at $98.00 on 2026-01-07; stock now at $118.64, near 52-week high.

Anders Jack sold 10,000 shares (8.5% of holdings) at $98.00, just 20 days before current price of $118.64—a transaction executed well below the 52-week high and during a powerful 52.3% rally over the past 30 days. At his same ticker, Revolution Medicines, Jack has an established pattern of well-timed exits: his prior two measurable sales (2024-10-11 and 2023-09-01) both preceded 90-day declines of -11.7% and -33.4% respectively, yielding a 2-of-2 well-timed rate at RVMD. However, the company remains deeply unprofitable with $-305.2M annual net income and zero quarterly revenue, creating structural uncertainty. The sale's timing—before a sharp rally—diverges from Jack's historical tendency to sell ahead of downturns, suggesting either a near-term execution need or a shift in the typical pattern at this biotech with volatile price action.

CFO Anders Jack sold 10,000 shares at $64.00 (stock up +35.5% in 30d, +77.3% in 90d); sells all well-timed at 90-day mark historically at RVMD.

Anders Jack, CFO of Revolution Medicines, sold 10,000 shares for $640,000 on 2025-11-11 at $64.00, reducing his holdings from 121.0K to 111.0K shares (8.3% reduction). The timing context is notable: RVMD has surged +35.5% over the prior 30 days and +77.3% over the prior 90 days, putting the stock within striking distance of its 52-week high of $65.83. His cross-ticker track record shows a 100.00% well-timed rate on 2 prior sells (negative 90-day returns), and at RVMD specifically, both prior sales (2024-10-11 and 2023-09-01) were followed by 90-day declines of 11.7% and 33.4% respectively, suggesting a pattern of selling ahead of pullbacks. The company's fundamentals remain challenged: latest quarter revenue was $0.00, the company posted a $-305.2M net loss for the most recent full year, and annual revenue growth was -100.0%, indicating a loss of commercial revenue. The combination of well-documented historical timing skill at this ticker, sharp recent price momentum, and persistent unprofitability creates a material signal for investors monitoring insider positioning.

CFO Anders Jack sold 10,000 RVMD shares at $50.30; prior same-ticker sale (2023-09-01) posted -33.4% return at 90 days.

Anders Jack, CFO of Revolution Medicines, sold 10,000 shares at $50.30 on 2024-10-11, reducing his holdings from 108,932 to 98,932 shares. This transaction occurs in an unprofitable company with negative net income of $-133.2M in the latest quarter and annual revenue decline of -67.3%, against a market cap of $8.2B. Notably, Jack's prior sale at RVMD on 2023-09-01 was well-timed at the 90-day horizon with a return of -33.4%, meaning the stock fell after that sale. His cross-ticker track record shows a 100.00% well-timed rate on prior sells with an average 90-day return of -33.4%, suggesting a pattern of selling before downturns. The current stock price of $48.99 is -3.0% from its 52-week high of $50.48, near the transaction price level, providing a near-term test of whether this sale again precedes a material decline.